Research & Policy

Corporate stories about Research & Policy across 3BL's network.

Latest in Research & Policy

The Impact of World Changing Technologies
Technology that makes a positive impact in our global communities, when and where it's needed most. That's why we strive to innovate in all of our businesses.
Reopening: It's All About the Execution
High expectations around reopening may already be substantially priced into markets, pointing to new risks around how the reopening actually plays out.
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021.
Healthcare Plastics Recycling Council Publishes White Paper on Advanced Recycling Technologies
The Healthcare Plastics Recycling Council (HPRC) has published a white paper, Advanced Recycling of Healthcare Plastics: An Opportunity for Circularity, to explore advanced recycling technologies.
With Lenovo, TechsoMed Is Spurring a Revolution in Cancer Treatment
The partnership between TechsoMed and Lenovo is enabling physicians to target cancer with never before seen precision.
Alkermes Shares Immuno Oncology Clinical Trial Research
We are pleased to share clinical trial data on our investigational #immunooncology therapy and are excited to be a part of the 17th EADO Congress and 2021 World Mobile Congress Interactive Virtual Meeting.
An Analysis on Bacterial Growth on Vinyl and Polished Concrete
Bacteria growth in flooring of hospitals, grocery stores, warehouses, etc. is extremely dangerous for human health. A more permeable surface is a result of a porous material that is more susceptible to this harmful bacterial growth.
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use
Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non-prescription, asymptomatic use of its BinaxNOW™ COVID-19 Ag Self Test for detection of COVID-19 infection.